Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Pre-Existing Myeloid Subclones May Account for a Subset of Acute Myeloid Leukemias and Myelodysplastic Neoplasms in Patients with Pre-Existing or Contemporary Lymphoid Disorders

Agnese Mattei, Giovanni Marconi, Sonia Ronconi, Delia Cangini, Michela Ceccolini, Claudio Cerchione, Irene Zacheo, Maria Benedetta Giannini, Marianna Norata, Giovanni Martinelli, Anna Ferrari, Maria Teresa Bochicchio, Martina Ghetti, Matteo Marchesini, Giorgia Simonetti, Gerardo Musuraca, Davide Nappi

Blood (2023) 142 (Supplement 1): 1475.

https://doi.org/10.1182/blood-2023-186760

Published: 2023

Journal Articles

Chemo or Chemo-Free Regimens in Heavily Pretreated Multiple Myeloma? Role of Bendamustine-Bortezomib-Dexamethasone (BVD) in NOVEL Agents' Era

Claudio Cerchione, Lucio Catalano, Davide Nappi, Anna Emanuele Pareto, Gerardo Musuraca, Sonia Ronconi, Michela Ceccolini, Giovanni Martinelli, Fabrizio Pane

Blood (2022) 140 (Supplement 1): 12585–12586.

https://doi.org/10.1182/blood-2022-170484

Published: 2022

Journal Articles

Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Claudio Cerchione, Davide Nappi, Gerardo Musuraca, Sonia Ronconi, Delia Cangini, Michela Ceccolini, Giovanni Martinelli

Blood (2022) 140 (Supplement 1): 13248–13249.

https://doi.org/10.1182/blood-2022-170561

Published: 2022

Journal Articles

Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Claudio Cerchione, MD PhD, Lucio Catalano, Davide Nappi, Anna Emanuele Pareto, Gerardo Musuraca, MD, Alessandro Lucchesi, MD, Sonia Ronconi, Michela Ceccolini, MD, Delia Cangini, Maria Benedetta Giannini, MD, Valeria Di Battista, Giorgia Simonetti, PhD, Andrea Ghelli Luserna Di Rorà, PhD, Fabrizio Pane, Giovanni Martinelli, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-143143

Published: 2020

Journal Articles

Unravel Inter-Tumor and Intra-Tumor Heterogeneity of Digitally Sorted Single Hodgkin and Reed Sternberg Cells Using Genome-Wide Copy Number Profiling

Chiara Mangano, PhD, Petrini Edoardo, PhD, Marianna Garonzi, PhD, Rossana Lanzellotto, PhD, Francesca Marzia Papadopulos, PhD, Chiara Bolognesi, Genny Buson, PhD, Alberto Ferrarini, PhD, Claudio Forcato, PhD, Giovanni Martinelli, MD, Francesca Fontana, Michela Ceccolini, MD, Francesco Fabbri, Pietro Fici, PhD, Giulia Gallerani, PhD, Cecilia Simonelli, MD, Gianni Medoro, PhD, Nicolò Manaresi, PhD

Blood (2018) 132 (Supplement 1): 1568.

https://doi.org/10.1182/blood-2018-99-109989

Published: 2018

Journal Articles

Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients

Gerardo Musuraca, MD, PhD, Serena De Matteis, Roberta Napolitano, Francesco Fabbri, Delia Cangini, MD, Michela Ceccolini, MD, Maria Benedetta Giannini, MD, Alessandro Lucchesi, MD, Sonia Ronconi, MD, Cristina Papayannidis, MD, Viviana Guadagnuolo, Giovanni Martinelli, MD, Paolo Savini, MD, Monica Tani, MD, Patrizia Tosi, MD, Dino Amadori, MD, Pier Paolo Fattori, MD, Wainer Zoli, Silvia Carloni

Blood (2013) 122 (21): 2289.

https://doi.org/10.1182/blood.V122.21.2289.2289

Published: 2013

Journal Articles

Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD)

Blood (2011) 118 (21): 1821.

https://doi.org/10.1182/blood.V118.21.1821.1821

Published: 2011

Journal Articles

Long Term Efficacy of Percutaneous Vertebroplasty in Multiple Myeloma (MM) Patients: Experience of the “Gruppo Ematologico Di Romagna” (GER)

Patrizia Tosi, MD, Annalia Molinari, MD, Michele Sintini, MD, Anna Merli, MD, Michela Ceccolini, MD, Manuela Imola, MD, Paolo Savini, MD, Silvana Pasini, MD, Anna M Mianulli, MD, Barbara Castagnari, MD, Pier P Fattori, MD, Giovanni Martinelli, MD, PhD, Alfonso Zaccaria

Blood (2011) 118 (21): 5123.

https://doi.org/10.1182/blood.V118.21.5123.5123

Published: 2011

Journal Articles

Prognostic Impact of Cytogenetic Abnormalities On Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated with Thalidomide-Dexamethasone Incorporated Into Double Autologous Stem-Cell Transplantation: An Analysis of 593 Patients

Blood (2010) 116 (21): 3562.

https://doi.org/10.1182/blood.V116.21.3562.3562

Published: 2010

Journal Articles

Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II “Bologna 2002” Study.

Blood (2009) 114 (22): 349.

https://doi.org/10.1182/blood.V114.22.349.349

Published: 2009

Journal Articles

Clinical and Prognostic Relevance of Magnetic Resonance Imaging of the Spine in Newly Diagnosed Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation.

Patrizia Tosi, M.D., Alessandro Petrucci, M.D., Lucia Pantani, M.D., Elena Zamagni, Paola Tacchetti, M.D., Giulia Perrone, M.D., Annamaria Brioli, M.D., Michela Ceccolini, M.D., Michele Baccarani, MD, Michele Cavo, MD

Blood (2009) 114 (22): 4885.

https://doi.org/10.1182/blood.V114.22.4885.4885

Published: 2009

Journal Articles

Thalidomide-Dexamethasone as Induction Therapy Prior to Autologous Stem-Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and Renal Failure.

Patrizia Tosi, M.D., Elena Zamagni, Paola Tacchetti, M.D., Michela Ceccolini, M.D., Giulia Perrone, M.D., Annamaria Brioli, M.D., Lucia Pantani, M.D., Alessandro Petrucci, M.D., Michele Baccarani, MD, Michele Cavo, MD

Blood (2009) 114 (22): 4934.

https://doi.org/10.1182/blood.V114.22.4934.4934

Published: 2009

Journal Articles

Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities.

Blood (2008) 112 (11): 1662.

https://doi.org/10.1182/blood.V112.11.1662.1662

Published: 2008

Journal Articles

Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide- Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma

Blood (2008) 112 (11): 158.

https://doi.org/10.1182/blood.V112.11.158.158

Published: 2008

Journal Articles

Economic and Social Burden of Multiple Myeloma in Italy: The Co.Mi.M. Study

Maria Teresa Petrucci, Elisabetta Calabrese, Anna Levi, Vincenzo Federico, Michela Ceccolini, Rita Rizzi, Alessandro Gozzetti, Patrizia Falco, Maria Caterina Cavallo, Simone Gerzelli, Mario Boccadoro, Francesco Lauria, Vincenzo Liso, Michele Cavo, Robert Foa

Blood (2008) 112 (11): 2393.

https://doi.org/10.1182/blood.V112.11.2393.2393

Published: 2008

Journal Articles

Bortezomib-Thalidomide-Dexamethasone as Primary Induction Therapy for Newly Diagnosed Multiple Myeloma Significantly Decreases Bone Resorption While Sparing Bone Formation as Compared to Thalidomide-Dexamethasone

Patrizia Tosi, MD, Elena Zamagni, MD, Paola Tacchetti, MD, Giulia Perrone, MD, Michela Ceccolini, MD, Anna Maria Brioli, MD, Maria Caterina Pallotti, MD, Lucia Pantani, MD, Alessandro Petrucci, MD, Michele Baccarani, Michele Cavo, MD

Blood (2008) 112 (11): 5117.

https://doi.org/10.1182/blood.V112.11.5117.5117

Published: 2008

Journal Articles

Baseline Thrombophilic Alterations and Risk of Venous Thromboembolism in 266 Multiple Myeloma Patients Primarily Treated with Thalidomide and High-Dose Dexamethasone.

Blood (2007) 110 (11): 3997.

https://doi.org/10.1182/blood.V110.11.3997.3997

Published: 2007

Journal Articles

Incorporation of Thalidomide into Up-Front Double Autologous Stem-Cell Transplantation (ASCT) for Multiple Myeloma Improves the Outcome in Comparison with Double ASCT without Thalidomide. Analysis of Baseline Factors Predicitve of Outcome.

Blood (2007) 110 (11): 447.

https://doi.org/10.1182/blood.V110.11.447.447

Published: 2007

Journal Articles

Clinical and Prognostic Relevance of Magnetic Resonance Imaging of the Spine in Newly Diagnosed Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation.

Patrizia Tosi, MD, Elena Zamagni, MD, Paola Tacchetti, MD, Eugenio Salizzoni, MD, Giulia Perrone, MD, Michela Ceccolini, MD, Annamaria Brioli, MD, Maria C. Pallotti, MD, Lucia Pantani, MD, Antonio de Vivo, MD, Michele Baccarani, MD, Michele Cavo, MD

Blood (2007) 110 (11): 4728.

https://doi.org/10.1182/blood.V110.11.4728.4728

Published: 2007

Journal Articles

Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM).

Blood (2007) 110 (11): 73.

https://doi.org/10.1182/blood.V110.11.73.73

Published: 2007

NARROW

Pre-Existing Myeloid Subclones May Account for a Subset of Acute Myeloid Leukemias and Myelodysplastic Neoplasms in Patients with Pre-Existing or Contemporary Lymphoid Disorders

Chemo or Chemo-Free Regimens in Heavily Pretreated Multiple Myeloma? Role of Bendamustine-Bortezomib-Dexamethasone (BVD) in NOVEL Agents' Era

Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Unravel Inter-Tumor and Intra-Tumor Heterogeneity of Digitally Sorted Single Hodgkin and Reed Sternberg Cells Using Genome-Wide Copy Number Profiling

Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients

Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD)

Long Term Efficacy of Percutaneous Vertebroplasty in Multiple Myeloma (MM) Patients: Experience of the “Gruppo Ematologico Di Romagna” (GER)

Prognostic Impact of Cytogenetic Abnormalities On Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated with Thalidomide-Dexamethasone Incorporated Into Double Autologous Stem-Cell Transplantation: An Analysis of 593 Patients

Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II “Bologna 2002” Study.

Clinical and Prognostic Relevance of Magnetic Resonance Imaging of the Spine in Newly Diagnosed Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation.

Thalidomide-Dexamethasone as Induction Therapy Prior to Autologous Stem-Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and Renal Failure.

Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities.

Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide- Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma

Economic and Social Burden of Multiple Myeloma in Italy: The Co.Mi.M. Study

Bortezomib-Thalidomide-Dexamethasone as Primary Induction Therapy for Newly Diagnosed Multiple Myeloma Significantly Decreases Bone Resorption While Sparing Bone Formation as Compared to Thalidomide-Dexamethasone

Baseline Thrombophilic Alterations and Risk of Venous Thromboembolism in 266 Multiple Myeloma Patients Primarily Treated with Thalidomide and High-Dose Dexamethasone.

Incorporation of Thalidomide into Up-Front Double Autologous Stem-Cell Transplantation (ASCT) for Multiple Myeloma Improves the Outcome in Comparison with Double ASCT without Thalidomide. Analysis of Baseline Factors Predicitve of Outcome.

Clinical and Prognostic Relevance of Magnetic Resonance Imaging of the Spine in Newly Diagnosed Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation.

Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only